Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17924754 | 1.00 | CNR2 (0.32) | CNR2LMNAPOLBTSHRCYP1A2 | |
| SCHEMBL17924750 | 1.00 | CNR2 (0.32) | CNR2LMNAPOLBTSHRCYP1A2 | |
| SCHEMBL2080035 | 0.68 | PPM1D (0.33) | — | |
| SCHEMBL5062067 | 0.65 | TSHR (0.41) | LMNAPOLBTSHRCYP1A2ALDH1A1 | |
| SCHEMBL22284304 | 0.65 | TSHR (0.36) | LMNAPOLBTSHRCYP1A2ALDH1A1 | |
| SCHEMBL22835194 | 0.65 | TSHR (0.36) | LMNAPOLBTSHRCYP1A2ALDH1A1 | |
| SCHEMBL23852199 | 0.64 | ALDH1A1 (0.41) | LMNAPOLBTSHRCYP1A2ALDH1A1 | |
| SCHEMBL28685905 | 0.64 | TSHR (0.44) | LMNAPOLBTSHRALDH1A1ALOX15 | |
| SCHEMBL18669353 | 0.64 | TSHR (0.38) | CNR2LMNAPOLBTSHRCYP1A2 | |
| SCHEMBL4702420 | 0.63 | CYP1A2 (0.45) | LMNAPOLBTSHRCYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071564-B1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-08-05 | — | — | EP | disclosed |
| US-9498479-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-20160206616-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206616-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | DPYD, SLC10A1, HPRT1 | CNR2 4399/4885LMNA 1975/4885POLB 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.